Lite Strategy Inc LITS

US Biotechnology
$1.44 โ–ฒ +0.70% (+$0.01)
Open $1.43
Prev Close $1.43
Day Range $1.37 โ€“ $1.53
52W Range $0.69 โ€“ $2.97
Market Cap $49.00M
Beta 0.04
EPS (TTM) $-1.74

๐Ÿ“‹ Company Profile

IndustryBiotechnology
CountryUS
ExchangeNASDAQ NMS - GLOBAL MARKET
CurrencyUSD
IPO Date2003-12-18
Shares Out.34,030,000
Websitelitestrategy.com/ โ†—
Phone13026587581
Employees4
Revenue$0
Gross Profit$0
Net Income-$23.7M
Free Cash Flow-$10.4M
Total Assets$57.8M
Total Liabilities$952,000
Equity$56.8M
About Lite Strategy Inc

Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.

Lite Strategy Inc is a publicly traded company under the ticker symbol LITS on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.

๐Ÿ“Š Analyst Ratings

6 analysts (2025-11-01)

Hold 3
Sell 1
Strong Sell 2

๐Ÿ“ฐ Latest News for LITS

๐Ÿ‘ฅ Related Stocks